Navigation Links
Memory Pharmaceuticals Reports First Quarter 2008 Financial Results
Date:5/14/2008

or and 5-HT6 antagonist programs. The

Company expects the savings from these initiatives to be in the range

of $2-3 million on an annualized basis.

-- Receipt of Nasdaq Notification. On April 2, 2008, the Company received

written notification from Nasdaq that, as of December 31, 2007, the

Company was not in compliance with the minimum $10.0 million

stockholders' equity requirement for continued listing under

Marketplace Rule 4450(a)(3). As required by Nasdaq, the Company has

submitted a plan to achieve and sustain compliance with all of The

Nasdaq Global Market listing requirements and the time frame required

to complete that plan.

Conference Call and Webcast Information

Memory Pharmaceuticals will hold a conference call on May 14, 2008, at 9:00 a.m. EDT to discuss the Company's first quarter 2008 financial results. The conference call will also be broadcast live from the "Investors" section of the Company's website. Memory Pharmaceuticals' senior management will host the conference call. Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: http://www.memorypharma.com under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter passcode number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008
2. Memory in artificial atoms
3. Memory Pharmaceuticals Receives Nasdaq Notification
4. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
5. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
6. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
7. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
10. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
11. ASU researchers improve memory devices using nanotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Robin Williams’ passing is a sad ... an individual. Symptoms range from slowness of voluntary ... and severe depression. Parkinson’s disease progressively gets worse ... producing neurons of the brain. As these patients ... and progressively gets worse, they look for options. ...
(Date:8/19/2014)... In November 2012, the European Union (EU) ... (PBRER) in a new PSUR – responding to the increasing ... of a drug. Adopted in many regions, the main objectives ... a comprehensive and critical analysis of new or emerging information ... any new evidence of the potential benefits of a drug; ...
(Date:8/18/2014)... (PRWEB) August 19, 2014 2014 ... Industry” is a professional and in-depth research report ... basic Linalool information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:8/18/2014)... WASHINGTON , Aug. 18, 2014   Sterne, ... law firm in Washington, DC , ... Inter Partes Review (IPR) with the U.S. ... Inc., a subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI). ... co-owned, or licensed by Myriad Genetics, Inc. These patents ...
Breaking Biology Technology:As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... , , ANNAPOLIS, Md., Dec. 21 ... company developing medical countermeasures against biological and chemical threats, today ... Board of Directors, increasing the Board to eight members. ... a firm providing advisory services in business risk management, homeland ...
... ... webinar, Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical ... ... free webinar, Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a ...
... ... of National Titles in 2009 Contest , ... Des Moines, Iowa (Vocus) December 18, 2009 -- DuPont congratulates Bill Wright, Walsh, ... the 2009 National Corn Growers Association (NCGA) Corn Yield Contest. Farmers planting Pioneer® brand ...
Cached Biology Technology:PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 2PharmAthene Appoints Jeffrey W. Runge, M.D. to the Company's Board of Directors 3Real Time to Manufacturing Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2DuPont Congratulates Wright for Highest Overall Yield with Pioneer Brand Hybrid 32N73 in 2009 NCGA Corn Yield Contest 2
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
(Date:8/20/2014)... University of Tbingen, Arizona State University, the Wellcome Trust ... Institute (Swiss TPH) isolated Mycobacterium pinnipedii from ... years old. The pathogen is a relative of the ... disease in humans today. These researchers assume that seals ... "The link to sea lions was unexpected" comments Sebastien ...
(Date:8/20/2014)... SILICON VALLEY, Calif., August 19, 2014 -- Bay Area ... to diagnose and simple to cure, applauds new research ... review journal Ticks and Tick-borne Diseases . ... in Northwest California are active throughout the year, making ... conducted by researchers at California Department of Public Health ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3
... A prototype drug created by researchers at the University ... of the virus responsible for severe acute respiratory syndrome, ... agents or vaccines for SARS, which killed almost 800 ... basis of their success, the researchers have received an ...
... of malaria is in prospect with a clinical drug trial ... in the trial would open the way to relief in ... fatal disease - over 500,000,000 people. , The Walter ... the Papua New Guinea Institute of Medical Research (PNGIMR) and ...
... research ?including research involving human embryonic stem cells ?is ... a position statement adopted by the Board of Directors ... the community of scientists on the front lines of ... belief that continued experimentation with human stem cells is ...
Cached Biology News:UIC developing drug for SARS 2UIC developing drug for SARS 3Old drug, new tricks: Prospects for slashing the impact of malaria 2AACR Favors 'full spectrum of stem cell research biology' 2AACR Favors 'full spectrum of stem cell research biology' 3